Market Insights Health Hospitals Inpatient Care

Neoplasm Treatment - EMEA

EMEA

In the EMEA region, the Neoplasm Treatment market is anticipated to witness significant growth, with projected revenue reaching a staggering US$87.83bn by the year 2024.
Moreover, this market is expected to exhibit a steady annual growth rate of 3.84% between 2024 and 2028, culminating in a market volume of approximately US$102.10bn by 2028.
It is worth noting that, in a global context, United States is poised to generate the highest revenue in the Neoplasm Treatment market, with an estimated US$90.56bn in 2024.
In EMEA, the neoplasm treatment market in Germany is witnessing a growing demand for innovative immunotherapies.

Key regions: Europe, Canada, Brazil, United States, United Kingdom

Market

Region

Region comparison

Currency

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on revenue received by hospitals from public or private sources, allocated to the country where the money is spent, including VAT if applicable.

Modeling approach / Market size:

Market sizes are determined by a bottom-up approach, based on a specific rationale for each market market. Next, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, public health spend, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.